This query was recently asked by one of our students and Our Junior Expert Ms Deepanwita took out time to write down a detailed article on this. We hope that it benefits you.

Answer: First of all I am happy to know that you are planning to pursue your masters in Engineering studies. Answer to this query in short is yes, you can apply for M.Tech program with a Low CGPA. For the procedure of how to go about please keep reading further.

The Central Inland Fisheries Research Institute (CIFRI) is the oldest premier research institute in the field of inland fisheries research and training in India. Established initially as Central Inland Fisheries Research Station by the Govt. of India at Kolkata in 1947, it assumed the status of an institute and shifted to Barrackpore (North 24-Parganas, West Bengal) in 1959. The Institute came under the administrative control of Indian Council of Agricultural Research in October 1967.
 

The main objectives of the institute were to conduct investigations for a proper appraisal of inland fisheries resources of the country and to evolve suitable methods for their conservation and optimum utilization. While fulfilling the above objectives, the Institute directed its research efforts towards understanding the ecology and production functions of inland water bodies available in the country like a river systems, lakes, ponds, tanks, reservoirs and floodplain wetlands. These studies have unraveled the complex tropic structure and functions vis-�-vis the environmental variables in different aquatic ecosystems. During the early 1970s, the Institute expanded its activities by initiating various All India co-ordinate Research Projects; such as composite fish culture and fish seed production, air breathing fish culture, ecology and fisheries management of freshwater reservoirs and brackish water fish farming.

Biocon is a research-driven, global healthcare company with a strong matrix of capabilities along the biopharmaceutical value chain. Focusing on unmet medical needs in cancer, diabetes and inflammatory diseases, we offer novel therapies on a platform of affordable innovation.

Excel Life Sciences (ELS) is a U.S.-based, India-focused provider of comprehensive trial management services. The company assist biopharmaceutical companies with placing and running their clinical trials at our India-leading network of investigative sites, while ensuring that all trials are conducted according to ICH - GCP guidelines and meet the highest standards of ethics and integrity.

ELS’ success is built around passionate and experienced individuals working alongside clients to accelerate clinical research and deliver new drugs and medical devices to the markets, while maintaining the highest standards of quality. As a trial management organization, company is also committed to improving and expanding the clinical research enterprise in India, evident through our presentations at conferences, peer-reviewed publications, and continuing relationships with academic institutions.
 

Products and Services provided by the Company

Intas Biopharmaceuticals Ltd. is an Indian biotechnology company headquartered in Ahmedabad, India. Located in the Moraiya,Ahmedabad,it is one of the leading biosimilar product manufacturer in Asia.

As an independent biopharmaceutical company of the Intas Group, the company has fully integrated biopharmaceutical operations with R&D facility and an EU-GMP certified bio-pharmaceutical manufacturing facility.

Intas Biopharma is also actively pursuing the Contract Research and Manufacturing Services(CRAMS) line of business. To expand its CRAMS business, Intas Biopharmaceuticals Ltd., in June 2008, acquired a US biotechnology corporation, Biologics Process Development Incorporated (BPD), based in Poway, California.

Products
Intas Biopharma has focused on biosimilars and has generic version of 3 of the top 10 blockbuster in its product basket. It launched its first product Neukine injection (Filgrastim)/ GCSF in July 2004.

Erythropoietin injection under the brand name of Erykine, for anemia due to critical illness like chemotherapy,was introduced in Aug 2005 and Interferon α2b under the brand name of Intalfa was launched in April 2007.

Intas Biopharma also considers itself first company in the world after the innovator, to introduce Pegylated version of GCSF (PEG-GCSF),under the brand name of Neupeg. Neupeg was launched in Aug 2007. The PEG (polyethylene glycol) form has a much longer half-life, reducing the necessity of daily injections.